EBR Systems Inc.
Health Care · USD
Price
$0.477
Cap
$215M
Earnings
0/2 beat
30d Trend
—
Near 52-week lows — potential value or falling knife
Target range: $2.43 – $2.59 (consensus: $2.48)
Consensus: Buy
Earnings history
Q2 2026
MISS
-0.03 vs
Q4 2025
MET
-0.06 vs -0.06
Key macro factors
Global economic challenges, as addressed by the IMF and World Bank, could impact healthcare spending and demand for new medical technologies, affecting EBR Systems' market adoption and growth prospects.
Access to capital and prevailing interest rates, influenced by overall financial market conditions and major US bank earnings, are critical for a developing medical device company like EBR Systems, which relies on funding for R&D and clinical trials for its investigational device.
The regulatory landscape and progress in clinical trials are paramount for EBR Systems, given its WiSE CRT System is an investigational device. Any changes in regulatory stringency or delays in the approval process can significantly impact the company's timeline to market and profitability.
EBR Systems, Inc. is a medical device company engaged in the treatment of patients suffering from cardiac rhythm diseases. It develops the wireless stimulation endocardially cardiac resynchronization therapy (WiSE CRT) System, an implantable cardiac pacing system designed to stimulate endocardial heart tissue without using leads, aiming to transform CRT delivery for patients who have not succeeded with conventional CRT.
QUANT SCORE
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.